semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Asthma Written informed consent and assent (if applicable) Male and female patients aged ≥12 years (or ≥lower age limit allowed by health authority and/or ethics committee/institutional review board approvals) A diagnosis of severe asthma, uncontrolled on GINA 4/5 asthma medication Evidence of airway reversibility or airway hyper reactivity FEV1 of ≤80% of the predicted normal value for patients aged ≥18 years; FEV1 of ≤90% for patients aged 12 to <18 years An ACQ score ≥1.5 A history of 2 or more asthma exacerbations within the 12 months prior to entering the study  Use of other investigational drugs within 5 half-lives of study entry, or within 30 days, whichever is longer Subjects who have participated in another trial of QAW039 A QTcF (Fridericia) ≥450 msec (male) or ≥460 msec (female) History of malignancy with the exception of local basal cell carcinoma of the skin Pregnant or nursing (lactating) women Serious co-morbidities Patients on greater than 20 mg of simvastatin, greater than 40 mg of atorvastatin, greater than 40 mg of pravastatin, or greater than 2 mg of pitavastatin
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Asthma Written informed consent Male and female patients aged ≥12 years A diagnosis of severe asthma, uncontrolled on GINA 4/5 asthma medication Evidence of airway reversibility or airway hyper reactivity FEV1 ≤80% of the predicted normal value for patients aged ≥18 years; FEV1 of ≤90% for patients aged 12 to <18 years An ACQ score ≥1.5 A history of 2 or more asthma exacerbations within the 12 months prior to entering the study  Use of other investigational drugs within 5 half-lives of study entry, or within 30 days, whichever is longer Subjects who have participated in another trial of QAW039 A QTcF (Fridericia) ≥450 msec (male) or ≥460 msec (female) History of malignancy with the exception of local basal cell carcinoma of the skin Pregnant or nursing (lactating) women Serious co-morbidities Patients on >20 mg of simvastatin, > 40 mg of atorvastatin, >40 mg of pravastatin, or >2 mg of pitavastatin
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 7.0-15.0,  Asthma Pediatric patients 7 to 15 years regardless of sex diagnosed with asthma by clinical suspicion and accurate diagnosis by spirometry positive flow limitation with bronchodilator reversibility Controlled pediatric Pneumology service Patients Patients whose parents accept the child's participation by signing the informed consent. For children over 12 years the least sign the informed consent personally  Patients with hypocalcemia or hypercalcemia Patients with kidney diseases such as kidney stones, hypercalciuria, renal tubular acidosis Patients with moderate to severe malnutrition
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Asthma Male and female adults with a physician diagnosis of persistent asthma for ≥12 months Existing treatment with medium to high dose inhaled corticosteroids in combination with a long-acting beta agonist for at least 3 months with a stable dose ≥1 month prior to Visit 1 (Screening Visit) Treatment with a third asthma controller for at least 3 months with a stable dose >=1 month prior to Visit 1 was allowed Pre-bronchodilator forced expiratory volume (FEV1) 55 to 85% of predicted normal  Participants <18 years or >65 years Fractional exhaled nitric oxide (FeNO) <26 parts per billion (ppb) at Visit 1 (Screening Visit) Chronic obstructive pulmonary disease or other lung diseases (eg, idiopathic pulmonary fibrosis, eosinophilic granulomatosis with polyangiitis [Churg-Strauss Syndrome]) which could impair lung function A participant who experienced an asthma exacerbation that resulted in emergency treatment, hospitalization due to asthma, or treatment with systemic steroids at any time from 1 month prior to Visit 1 A participant who had experienced an upper or lower respiratory tract infection within the 4 weeks prior to Visit 1 Evidence of lung disease(s) other than asthma Previous smoker (smoking history >10 pack-years) or current smoker (within 6 months prior to Visit 1) Comorbid disease that might interfere with the evaluation of investigational medicinal product or conduct of study procedures (e.g., bronchoscopy) Anti-immunoglobulin E (IgE) therapy (omalizumab) or any other biologic therapy within 6 months of Visit 1 Exposure to another investigative study medication within a time period prior to Visit 1 that is less than 5 half-lives of the study medication
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 14.0-65.0,  Asthma Clinically diagnosed Asthmatic patients aged from14 to 65 years； Had a had a normal chest radiographic result； Had a baseline spirometry with the forced expiratory volume in one second (FEV1) of not less than 60% predicted； Without acute upper respiratory tract infection for the past 2 weeks  Smokers； Had a poor cooperation to the test or limited understandings Had a past confirmed history of respiratory disease other than bronchial asthma (COPD, bronchiectasis, pulmonary thromboembolism, etc.) or other severe systemic disease（myocardial infarction, malignant tumor, etc.） Pregnancy or breast-feeding women Taken related drugs before measurements（Leukotriene receptor antagonists (LTRA) for 5 days，oral glucocorticosteroid or anti-histamine for 3 days，oral xanthenes or long-acting bronchodilators for 2 days，inhaled corticosteroid or long-acting bronchodilator for a day , short-acting bronchodilator for 4 hours ）
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 2.0-15.0,  Asthma Clinical diagnosis of moderate or severe asthma exacerbations to 15 years old Served in the pediatric emergency department of naval high specialty General Hospital from September to December 2015 Signing the consent by the parents  Coexistence of lung disease Severe kidney disease Severe liver disease Pregnancy Known previous reaction to magnesium Parents who have not signed the agreement Patients without a clinical history of asthma Clinical diagnosis of mild asthma attack Previously included in the study Presence of comorbidities that endanger the patient's life
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cystic Fibrosis Volunteers with Cystic Fibrosis and lung disease with chest hemiperímetro ≥ 37 cm  Episode of pulmonary infectious exacerbations in the last four weeks or during the study period; cor pulmonale; facial deformity that causes air leakage; facial trauma and recent face or esophagus surgery; chest pain; hemoptysis in the last week; continued use of supplemental oxygen (> 8 hours / day); hemoptysis; hemodynamic instability and do not understand the use and command of the techniques used
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 0.25-18.0,  Hypertension, Pulmonary Patient must be an incident patient, i.e.newly diagnosed with PH Age at time of diagnosis is at least 3 months and less than 18 years Patients must present with PH belonging to one of the following categories Group 1 according to updated Nice clinical classification Group 3 according to updated Nice clinical classification Group 4 according to updated Nice clinical classification Group 5 according to updated Nice clinical classification PH confirmed by heart catheterisation (HC) At HC, the patient must present with mean pulmonary arterial pressure (PAP) of at least 25 mmHg at rest, a pulmonary vascular resistance index (PVRi) equal to or below 3 Wood units*m^2 and mean pulmonary arterial wedge pressure (PAWP) below or equal to 15 mmHg In case of congenital heart disease (CHD) patients who had undergone palliative procedure or repair to close systemic to pulmonary shunt, the diagnosis of PH must have been confirmed by HC at least 6 months after surgery/palliative procedure took place  Patients belonging to Group 2 according to updated Nice clinical classification
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 16.0-70.0,  Asthma All patients must be able to give informed consent. The definition of severe asthma will be on the basis of Uncontrolled asthma: three or more of the following features present in any week in the previous 4 weeks Daytime symptoms more than twice per week Any limitation of activities Nocturnal symptoms once or more per week Need for reliever treatment more than twice per week Pre bronchodilator FEV1 <80% predicted or personal best OR Frequent severe exacerbations (≥2 per year) OR Require prescription of daily or alternate day oral corticosteroids (OCS) to achieve asthma control despite the prescription of high dose inhaled corticosteroids (>1000mcg fluticasone propionate daily or equivalent) or maintenance oral corticosteroids plus a long acting beta agonist or one other controller medication (for example anti-cholinergics, leukotriene receptor antagonists or theophylline)  • Current smoker, or Ex-smoker with a >10 year pack history or having smoked within the past 6 months Significant alternative diagnoses that may mimic or complicate asthma, in particular dysfunctional breathing, panic attacks, and overt psychosocial problems (if these are thought to be the major problem rather than in addition to severe asthma) Significant other primary pulmonary disorders in particular pulmonary embolism, pulmonary hypertension, interstitial lung disease and lung cancer Subjects with emphysema and bronchiectasis should only be excluded if this is thought to be the major pulmonary disorder rather than in addition to severe asthma Diagnosis or current investigation of occupational asthma Any subjects currently participating, or having participated within 3 months of the first dose in a study using a new molecular entity, or the first dose in any other study investigating drugs
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 12.0-80.0,  Asthma Vitamin D Deficiency Disease Exacerbation All the consecutive patients with bronchial asthma of any severity, who presented for a scheduled visit at our Respiratory Clinic during the period October 2012-March 2013 and who had at least one year regular follow-up every three months  Acute exacerbation in the last month and treatment with vitamins and dietary supplements in the last year
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 7.0-17.0,  Childhood Asthma Informed written consent signed by a parent or guardian of the patient and by the patient (asthma and healthy controls) Diagnosis of mild asthma and moderate asthma according to the of the Global Initiative for Asthma 2014 (Global Strategy for Asthma Management and Prevention. National Institutes of Health 2014), treated with inhaled steroids and who come to the outpatient Clinic of Pediatric Pulmonology at Hospital Infantil de Mexico An evolution of the asthma > 6 months Able to perform spirometry test and multiple-breath washout test No exacerbation of asthma in the past 4 weeks Accept a washout period (without treatment) for 1 week before the realization of studies of pulmonary function Accept the use of necessary short-acting B2 bronchodilator during the washout period Do not suffer from any other chronic disease other than asthma  Patient with acute or chronic pulmonary disease other than asthma Patient with asthma exacerbation in the last 4 weeks prior to in the study Patients with a diagnosis of severe asthma Other co-morbidities
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Asthma Male or female volunteers aged 18-65 years with persistent asthma and on inhaled corticosteroids (at least 400 micrograms beclomethasone dipropionate equivalent dose daily) Current smoker Forced Expiratory Volume in 1 second (FEV1) ≥ 60 % predicted Ability to give informed consent Agreement for their General Practitioner to be made aware of study participation and to receive feedback as relevant to the participant's well being  Other significant respiratory diseases, in the opinion of the investigator, such as COPD or bronchiectasis An asthma exacerbation or respiratory tract infection requiring systemic steroids and/or antibiotics within 1 month of the study commencement or 3 months if hospital admission was required Any clinically significant medical condition that may endanger the health or safety of the participant Participation in another drug trial within 30 days before the commencement of the study Pregnancy or lactation Unable to comply with the procedures of the protocol Unable or unwilling to consent
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 6.0-16.0,  Asthma to 16 years old Physician-diagnosed asthma for at least one year At least one severe asthma exacerbation in the previous year Use of asthma medications (daily controller medication [ICS or leukotriene inhibitor] or inhaled β2-agonist [at least three days per week]) for at least six months in the previous year Vitamin D insufficiency (i.e., serum vitamin D (25(OH)D level <30 ng/ml (75 nmol/L)) FEV1 ≥70 % of predicted Positive bronchodilator response (i.e., increase in FEV1 ≥8% from baseline after inhaled short acting beta agonist or increased airway responsiveness to methacholine (PC20 ≤8 mg/ml if not on ICS or PC20 ≤16 mg/ml if on ICS) Study protocol (i.e., age-appropriate dose of Fluticasone and no other asthma controller medications) approved by the child's regular doctor Parental consent and child's assent to participate in the study. Additional applied after the run-in period, to be eligible for randomization Adherence with ICS and study medication (≥75% use [at least 21 of 28 days]) during the run-in period  Serum calcium >10.8 mg/dl Serum 25(OH) D <14 ng/ml (35 nmol/L) Chronic respiratory disorder other than asthma Severe asthma (intubation for asthma at any time OR ≥3 hospitalizations for asthma in previous year OR ≥6 severe asthma exacerbations in previous year) Hepatic/renal disease, rickets, malabsorption, or other diseases that would affect vitamin D metabolism Current smoking, or former smoking if ≥5 pack-years Immune deficiency, cleft palate or Down's syndrome Treatment with anticonvulsants or ≥1,000 IU/day of vitamin D2 or D3 Chronic oral corticosteroid therapy Inability to perform acceptable spirometry